Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent Lymphoma (REVERSE_2021)

Azienda Unita Sanitaria Locale Reggio Emilia

Status

Enrolling

Conditions

Indolent B-Cell Lymphomas

Indolent B Cell Lymphoma

Diffuse Large B Cell Lymphoma (DLBCL)

Study type

Observational

Funder types

Other

Identifiers

NCT06822829

446/2023/OSS/IRCCSRE

Details and patient eligibility

About

Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice.

The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma.

More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 years or older at the time of diagnosis.
Previous diagnosis of diffuse large B-cell lymphoma with/without a discordant component of indolent B-cell lymphoma, or previous diagnosis of diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma.
First-line treatment for diffuse large B-cell lymphoma.
Histologically documented relapse of indolent B-cell lymphoma, diagnosed between 2010 and 2020.
Availability of the histological report of the relapse.
Availability of clinical and laboratory data related to both the initial diagnosis and relapse.
Availability of follow-up data.
Consent to participate in the study and signing of the specific informed consent form (for living and/or contactable patients).

Exclusion criteria